Filing Flows

Filing Flows › Vericel (VCEL) › Q4 2025

Vericel (VCEL) Q4 2025 earnings results (fourth quarter 2025)

10-K filed Feb 26, 2026

Vericel (VCEL) reported revenue of $92.9M for the fourth quarter 2025 (Q4 2025), +23% from a year earlier and +38% from the quarter before. Operating margin was 24.1%, net earnings $23.2M (25.0% of revenue).

Revenue$92.9M
Year over year+23%
Quarter over quarter+38%
Operating margin24.1%
Net earnings$23.2M

Vericel, Q4 2025: revenue $92.9M (+23% year over year), operating margin 24.1%, net earnings $23.2M, operating cash flow $15.0M. The chart follows the revenue to costs, profit and cash.

Q4 2025AmountQ/QY/Y
Revenue$92.9M+38%+23%
Gross profit$73.1M+47%+25%
Operating profit$22.4M+550%+21%
Net earnings$23.2M+358%+17%
Operating cash flow$15.0M-32%-32%
Free cash flow$12.8M-34%+52%

What changed

Revenue was $92.9M in Q4 2025, up 23% year over year and up 38% from the previous quarter.

Gross margin was 78.7%, up 1.1 points from a year earlier. Operating profit was $22.4M, a 24.1% margin (down 0.4 points year over year). Of the extra revenue versus a year earlier, 22% reached operating profit, below the 25% margin then. Operating expenses grew 27% against revenue growth of 23%. The fastest-growing cost line was Research & development (+47%). Net earnings were $23.2M, up 17% year over year. The effective tax rate was 0.0%.

Operating cash flow was $15.0M (down 32% year over year), 65% of net earnings. Non-cash charges added back $3.1M of depreciation and amortization and $8.4M of share-based compensation. Working capital and other items used $19.7M. Capital expenditures of $2.2M left free cash flow of $12.8M.

Questions

What was Vericel's revenue in the fourth quarter 2025?

Vericel (VCEL) reported revenue of $92.9M for the fourth quarter 2025 (Q4 2025), +23% from a year earlier and +38% from the quarter before.

Was Vericel profitable in the fourth quarter 2025?

Operating profit was $22.4M (24.1% of revenue) and net earnings $23.2M.

Open the interactive Sankey →

Source: Vericel 10-K on SEC EDGAR.